Real-world Effectiveness and Safety of Tixagevimab/Cilgavimab Lower Dosage Regimen in Pre-Exposure Prophylaxis in Patients Undergoing Treatment for Chronic Lymphocytic Leukemia (IWCLL 2023)
Total number of patients 81 age at CLL diagnosis, median (range) 62 (37–79) age at tixagevimab/cilgavimab administration, median (range) 71 (42–90) males, n (%) 44 (54) prognostic markers unmutated iGhV, n (%)* 57 (73) Del(17p) and/or mutation TP53, n (%) 20 (25) Del(11q), n (%) 32 (40) Trisomy 12, n (%) 13 (16) Del13q as a sole abnormality, n (%) 15 (19) Complex karyotype, n (%) 11 (14) hypogammaglobulinemia, n (%)† 38 (52) obesity, n (%) ‡ 28 (35) CiRS score, median (range) 6 (2–14) major comorbidities, n (%) 49 (60) SaRS-CoV-2 vaccine in history, n (%) 73 (90) Type of treatment for CLL at administration of tixagevimab/cilgavimab idelalisib, n (%) 3 (4) Chemoimmunotherapy, n (%) 6 (7) Venetoclax, n (%) 32 (40) anti-CD20 monoclonal antibody, n (%) 35 (43) BTk inhibitor, n (%) 41 (51) *iGhV available in 78 pts; †data available in 73 pts; ‡defined as body mass index (Bmi) ≥ 30...Only 1 (1%) patient on ibrutinib reported red skin nodules five days post T/C prophylaxis... Our data show that T/C 150/150 mg failed to prevent COVID-19 in about a third of patients during CLL treatment. However, most CLL patients who developed COVID-19 after prophylactic T/C had a mild infection with a low hospitalization rate. We will present updated results, including a comparison with CLL patients who did not receive prophylaxis with T/C.